risk capital investments in biotechnology and medical device companies totaled $47 billion in 2002 or 22 percent of all investing.

risk capital investments in biotechnology and medical device companies totaled $47 billion in 2002 or 22 percent of all investing, the highest proportion in seven years, according to the MoneyTree scan from PricewaterhouseCoopers, Thomson luck Economics and the National chance Capital Association (NYCA).

throughout the past five years, investing in life sciences has continued at a comparatively steady pace relative to the luck capital market as a whole. The sector no other than partially benefited from the colossal surge in venture capital investing that began in 1998 on the other hand it also ...

...